Metformin Inhibitors
1 drugsAbout Metformin
Metformin is a cornerstone medication for type 2 diabetes, primarily working by reducing hepatic glucose production and improving insulin sensitivity, though its precise mechanism is still under investigation.
Metformin represents a significant drug target in the metabolic therapeutic area, underscored by its enduring clinical success in managing diabetes; however, there is currently no genetic evidence linking Metformin to specific diseases.
Currently, SEGLUROMET is the only FDA-approved drug containing Metformin, developed by Merck and approved in 2017, highlighting a limited drug landscape for this target.
Top Metformin Drugs
Merck is the only company with an approved drug containing Metformin.
The market's low competition presents an opportunity for new entrants to develop Metformin-based therapies.
Metformin Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Metformin, using small molecule modality.
Exploring alternative modalities could expand therapeutic options and address unmet needs.
Metformin Clinical Trials 35 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Metformin. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 10 | 0 | 0 | 100% |
| Phase 2 | 4 | 3 | 0 | 1 | 100% |
| Phase 3 | 13 | 12 | 1 | 0 | 92% |
| Phase 4 | 8 | 3 | 2 | 3 | 60% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Metformin Drug Approval Timeline (2017 - 2017)
The first and only drug approval was SEGLUROMET in 2017.
The lack of recent approvals suggests potential saturation or a need for innovative approaches.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 14 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Metformin. A trial counts if an approved drug acting on Metformin is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.